Developer docs
API playgroundTry for free, no card

Search company profiles

Genesis Molecular AI

Full company profile

uuid0002u41

Namestring
Genesis Molecular AI
Legal namestring
Genesis Molecular AI, Inc.
Websiteurl
genesis.ml
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Genesis Molecular AI (formerly Genesis Therapeutics) is a private, venture-backed AI drug discovery company founded in 2019 by Evan Feinberg in South San Francisco. The company develops GEMS (Genesis Exploration of Molecular Space), an agentic AI operating system for small molecule drug discovery that integrates foundation models, autonomous agents, and exploratory tooling used by chemists across the full design-make-test cycle. GEMS is powered by Pearl, Genesis's flagship generative 3D foundation model for protein-ligand cofolding — the first model to clearly surpass AlphaFold 3 on public benchmarks (Runs N' Poses, PoseBusters, OpenBind) and on Genesis's internal crystal structures, achieving sub-angstrom accuracy via a SO(3)-equivariant diffusion architecture trained on physics-based synthetic data. The platform also includes DeCAF-Pearl, a flow map distilled variant delivering ~5x inference speedup, and predictive capabilities spanning potency, selectivity, and 30+ ADME properties.

The company operates a B2B enterprise partnership model with global pharmaceutical companies, structured as multi-target, multi-year collaboration agreements. Disclosed deal economics include a $35M upfront from Gilead (Sept 2024, three initial targets), $30M upfront from Incyte (Feb 2025, two oncology targets), and $120M upfront from Incyte (May 2026 expansion, including $40M equity), with up to $232M in milestones per program and over $1B in potential aggregate milestones across five initial targets. Genesis also advances a wholly-owned internal pipeline across oncology (pan-mutant PIK3CA inhibitors, programmed cell-death promoters) and immunology (validated and novel autoimmune targets), and operates three U.S. offices (San Mateo HQ + AI research, San Diego wet lab, New York AI research). The company has raised over $300M cumulatively across a $52M Series A (Rock Springs, Dec 2020) and a $200M oversubscribed Series B (a16z, Fidelity, BlackRock, NVIDIA NVentures, Aug 2023), and reports $16.1M in 2025 ARR per third-party data.

Short descriptiontext

Genesis Molecular AI is a private AI drug discovery company, founded in 2019, that develops the GEMS platform and Pearl foundation model to accelerate small molecule discovery. It partners with major pharmaceutical companies (Incyte, Gilead) on multi-target collaborations and advances an internal pipeline in oncology and immunology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBurlingame, United States
HQ citystring
Burlingame
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, foundation models, protein-ligand cofolding, small molecule design, computational chemistry
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAACAA
Foundation Model Developers (LLM/Multimodal Model Labs)
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Partnership Upfront Cash Payments
TypeTransaction Fee
Description

Large upfront cash payments received as part of multi-year pharma collaboration deals. Incyte paid $80M upfront cash in the 2026 expanded deal; Gilead paid $35M upfront in 2024.

forbes.com
2Equity Investments from Partners
TypeSubscription Recurring
Description

Strategic partners purchase equity in Genesis as part of deal structures. Incyte made a $40M equity purchase in Genesis as part of the 2026 expanded agreement; NVIDIA also made an equity investment (November 2024).

businesswire.com
3Milestone Payments
TypeLicensing Royalties
Description

Preclinical, clinical development, regulatory, and sales milestones up to $232M per program. Incyte deal could pay over $1B in milestones across the five initial targets, with several billion more possible with additional targets.

businesswire.com
4Royalties on Approved Products
TypeLicensing Royalties
Description

Tiered royalties on sales of any approved collaboration products commercialized by partners.

businesswire.com
5Recurring Research Funding
TypeSubscription Recurring
Description

Recurring research funding from Incyte to support AI model training and inference compute workloads as part of the expanded 2026 agreement.

businesswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Bespoke multi-target partnership pricing negotiated per pharma collaboration
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / not publicly disclosed. Examples in the public record: Gilead 2024 deal — $35M upfront for 3 initial targets; Incyte 2025 initial deal — $30M upfront for 2 oncology targets; Incyte 2026 expansion — $120M upfront ($80M cash + $40M equity) + recurring research funding + up to $232M milestones per program + >$1B in potential aggregate milestones + royalties.

genesis.ml
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1GEMS
Description

Genesis Exploration of Molecular Space — the AI operating system/platform for drug discovery integrating foundation models, agents, and exploratory tooling for chemists.

genesis.ml
+1 more record
Core offering1 text field

Genesis Molecular AI builds GEMS (Genesis Exploration of Molecular Space), an AI operating system for drug discovery that integrates proprietary foundation models, autonomous agents, and exploratory tooling used by chemists across the design-make-test cycle. The platform is powered by Pearl, a generative 3D foundation model for protein-ligand cofolding, and is deployed both into partners' R&D workflows via multi-target collaborations and into Genesis's own internal small molecule pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 15% relative improvement over AlphaFold 3 on Runs N' Poses protein-ligand cofolding benchmark
+5 more records
Product overview1 text field

Genesis Molecular AI offers a unified platform-plus-foundation-model product architecture. The flagship offering is GEMS (Genesis Exploration of Molecular Space), the AI operating system for drug discovery, which integrates foundation models, agents, and exploratory tooling for chemists. GEMS is powered by Pearl, Genesis' industry-leading foundation model for 3D biomolecular structure prediction that was the first model to clearly surpass AlphaFold 3 on protein-ligand cofolding. The architecture also includes DeCAF-Pearl (a distilled flow map variant achieving ~5x inference speedup) and the production Pearl System (which adds inference-time scaling and physics+AI-based pose ranking). GEMS powers both Genesis' internal wholly-owned pipeline (oncology programs including PIK3CA and programmed cell death, plus immunology programs) and major pharma partners' pipelines (Incyte multi-target collaboration in oncology, hematology, and inflammation; Gilead multi-target collaboration against hard-to-drug targets).

Product and service6 records
1GEMS (Genesis Exploration of Molecular Space)
CategoryAI drug discovery platform
Description

End-to-end agentic AI platform for small molecule drug discovery that integrates foundation models, autonomous agents, and exploratory chemistry tooling; used by pharma partners (Incyte, Gilead) and Genesis's internal discovery teams to generate, predict, and triage drug candidates.

2Pearl Foundation Model
CategoryAI foundation model
Description

Generative 3D foundation model for protein-ligand cofolding and structure prediction built on a SO(3)-equivariant diffusion architecture trained on physics-based proprietary synthetic data; achieves sub-angstrom accuracy and powers GEMS for both internal pipeline and partner programs.

3DeCAF-Pearl (Denoiser Cofolding All-atom Flowmap model)
CategoryAI foundation model variant
Description

First flow map model for all-atom cofolding, distilled from Pearl, providing ~5x faster inference at near-teacher accuracy to support high-throughput virtual screening and large-scale synthetic data generation for GEMS.

4Pearl System (Production Cofolding System)
CategoryAI production model system
Description

Production cofolding system combining the Pearl foundation model with inference-time scaling techniques and physics+AI-based pose ranking, deployed inside GEMS to support active drug discovery programs against hard-to-drug targets.

5Multi-Target Pharma Collaboration (Incyte)
CategoryPharma collaboration deal
Description

Bespoke multi-year, multi-target collaboration service where Genesis deploys the GEMS platform and forward-deployed drug hunters and engineers alongside partner R&D teams to co-develop differentiated small molecule drug candidates against partner-selected targets; includes exclusive development/commercialization rights, milestone payments, and royalties for the partner.

6Multi-Target Pharma Collaboration (Gilead)
CategoryPharma collaboration deal
Description

Bespoke multi-year, multi-target collaboration service where Genesis deploys the GEMS platform against hard-to-drug targets selected by Gilead; deal economics include upfront cash, milestone payments, and royalties on approved products.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

Significant expansion of the 2025 collaboration. Genesis receives $120M upfront ($80M cash + $40M equity) plus recurring research funding and is eligible for up to $232M in milestones per program, $1B+ in total milestones across five initial targets, and royalties. Incyte will provide proprietary experimental data to train GEMS — among the first major pharma-AI collaborations to power foundation model training with a partner's proprietary data. The companies will add at least five new collaboration targets (with the option to nominate more), and Incyte will have exclusive rights to develop and commercialize any resulting products.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Initial 2025 strategic AI-focused research collaboration. Genesis received $30M upfront for two oncology targets using the GEMS AI platform. Genesis and Incyte are co-developing differentiated small molecule drug candidates against Incyte-selected targets, with Genesis providing AI-driven design and Incyte providing R&D and commercial capabilities.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-13
Description

Equity investment and collaboration to optimize key computational methods for AI-powered drug discovery. Jointly announced Pearl at GTC 2025, with co-authorship of Pearl's technical report. NVIDIA's cuEquivariance kernels provide up to 15% training speedup and up to 80% inference speedup; collaboration accelerated Pearl inference 10–80% and unlocked 2.3–2.8x end-to-end speedup on B200 vs. baseline H100. NVIDIA's Triton and cuEquivariance were instrumental in accelerating Pearl inference.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-10
Description

Strategic collaboration to discover and develop novel therapies. Genesis received $35M upfront payment to collaborate on 3 initial hard-to-drug targets using the GEMS AI platform. The companies work closely together on discovery and development.

5OpenBind Consortium
Strategic tierMinorTypeOthers
Description

OpenBind Consortium provided the first public structure-affinity benchmark for structure-based molecular AI; Genesis evaluated Pearl on OpenBind's EV-A71 2A 802-compound benchmark, achieving state-of-the-art zero-shot performance.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with Ron Shprints, Peter Holderrieth, Juno Nam, Rafael Gómez-Bombarelli, and Tommi Jaakola on the DeCAF-Pearl work and related research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with Nicholas Matthew Boffi on the DeCAF-Pearl work and related research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research collaboration with Joey Bose (UCL and Mila) on the DeCAF-Pearl work and related research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public AI-driven drug discovery company combining high-throughput wet-lab experimentation with foundation models and partnering with major pharma (Roche/Genentech, Bayer, Sanofi). Comparable in scale, multi-target partnership model, and ambition to industrialize early-stage discovery.

2Isomorphic Labs
TypeDirect peer
Description

Alphabet/DeepMind spinout applying AlphaFold-derived foundation models to small molecule and biologics drug discovery, with multi-target pharma partnerships (e.g., Novartis, Eli Lilly). Directly comparable AI-first discovery platform with anchor pharma deals and proprietary structure-prediction models.

TypeDirect peer
Description

AI-driven drug discovery company combining ML, induced pluripotent stem cell biology, and high-throughput data generation, with multi-year partnerships with Bristol Myers Squibb, Gilead, and Eli Lilly. Closely comparable in business model, partnership economics, and biotech+ML integration thesis.

TypeDirect peer
Description

AI drug discovery company launched in 2024 with ~$1B from Sequoia and a re-purposed Illumina R&D engine, focused on foundation models for biology and small molecules. Comparable as a well-capitalized AI drug-discovery platform pursuing both partnerships and internal programs.

TypeDirect peer
Description

Public computational chemistry and AI drug discovery company offering physics-based simulation platforms and co-developing an internal and partnered pipeline. Comparable in combining physics-based and ML approaches and selling into pharma R&D, though more mature and platform-product-led.

TypeDirect peer
Description

Flagship Pioneering-backed AI drug discovery company developing generative foundation models (e.g., Chroma) for proteins and increasingly small molecules, with major pharma partnerships (e.g., Novartis, Amgen). Closely comparable in generative AI foundation-model thesis and enterprise partnership model.

TypeDirect peer
Description

Public AI-driven small molecule discovery company with end-to-end platform and pharma partnerships (e.g., Sanofi, Bristol Myers Squibb, Roche). Closely comparable in target class (small molecules), partnership economics, and platform-plus-internal-pipeline strategy.

TypeDirect peer
Description

AI drug discovery company using structure-based and 3D molecular models (AtomNet) to discover small molecules, with a broad portfolio of pharma partnerships. Comparable in leveraging 3D structure prediction and partnership-led GTM, though earlier-stage and narrower on foundation-model capability.

TypeEmerging player
Description

AI-driven small molecule discovery company combining physics-based simulation with generative AI, with NVIDIA collaboration and a partnership with AstraZeneca/Illumina. Closely comparable in NVIDIA partnership pattern and physics+ML foundation, though smaller in scale and fewer named anchor pharma partners.

TypeDirect peer
Description

Public AI drug discovery company focused on target identification and small molecule design, with pharma collaborations (e.g., Merck KGaA, AstraZeneca). Comparable in AI-first small-molecule and target discovery positioning, though differentiated by an emphasis on target ID over cofolding.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature12 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genesis Molecular AI

AI Drug Discoverygenesis.ml

Genesis Molecular AI is a private AI drug discovery company, founded in 2019, that develops the GEMS platform and Pearl foundation model to accelerate small molecule discovery. It partners with major pharmaceutical companies (Incyte, Gilead) on multi-target collaborations and advances an internal pipeline in oncology and immunology.

What Genesis Molecular AI does

Genesis Molecular AI (formerly Genesis Therapeutics) is a private, venture-backed AI drug discovery company founded in 2019 by Evan Feinberg in South San Francisco. The company develops GEMS (Genesis Exploration of Molecular Space), an agentic AI operating system for small molecule drug discovery that integrates foundation models, autonomous agents, and exploratory tooling used by chemists across the full design-make-test cycle. GEMS is powered by Pearl, Genesis's flagship generative 3D foundation model for protein-ligand cofolding — the first model to clearly surpass AlphaFold 3 on public benchmarks (Runs N' Poses, PoseBusters, OpenBind) and on Genesis's internal crystal structures, achieving sub-angstrom accuracy via a SO(3)-equivariant diffusion architecture trained on physics-based synthetic data. The platform also includes DeCAF-Pearl, a flow map distilled variant delivering ~5x inference speedup, and predictive capabilities spanning potency, selectivity, and 30+ ADME properties.

The company operates a B2B enterprise partnership model with global pharmaceutical companies, structured as multi-target, multi-year collaboration agreements. Disclosed deal economics include a $35M upfront from Gilead (Sept 2024, three initial targets), $30M upfront from Incyte (Feb 2025, two oncology targets), and $120M upfront from Incyte (May 2026 expansion, including $40M equity), with up to $232M in milestones per program and over $1B in potential aggregate milestones across five initial targets. Genesis also advances a wholly-owned internal pipeline across oncology (pan-mutant PIK3CA inhibitors, programmed cell-death promoters) and immunology (validated and novel autoimmune targets), and operates three U.S. offices (San Mateo HQ + AI research, San Diego wet lab, New York AI research). The company has raised over $300M cumulatively across a $52M Series A (Rock Springs, Dec 2020) and a $200M oversubscribed Series B (a16z, Fidelity, BlackRock, NVIDIA NVentures, Aug 2023), and reports $16.1M in 2025 ARR per third-party data.

Genesis Molecular AI firmographics

Firmographics
Name
Genesis Molecular AI
Legal name
Genesis Molecular AI, Inc.
Website
https://genesis.ml
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Genesis Molecular AI is a private AI drug discovery company, founded in 2019, that develops the GEMS platform and Pearl foundation model to accelerate small molecule discovery. It partners with major pharmaceutical companies (Incyte, Gilead) on multi-target collaborations and advances an internal pipeline in oncology and immunology.
Ownership category
akta.pro rank

Genesis Molecular AI industry classification

Industry
Product category
AI Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAAACAA
Foundation Model Developers (LLM/Multimodal Model Labs)
Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Foundation Models & Generative AI (LLMs, multimodal)
SECONDARYHLAGAJAE
Cheminformatics & Molecular Modeling / CADD
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • AI drug discovery
  • Foundation models
  • Protein-ligand cofolding
  • Small molecule design
  • Computational chemistry

Where Genesis Molecular AI is headquartered

Location

Headquarters

HQ city
Burlingame
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Genesis Molecular AI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Partnership Upfront Cash Payments: Large upfront cash payments received as part of multi-year pharma collaboration deals. Incyte paid $80M upfront cash in the 2026 expanded deal; Gilead paid $35M upfront in 2024.
  2. Equity Investments from Partners: Strategic partners purchase equity in Genesis as part of deal structures. Incyte made a $40M equity purchase in Genesis as part of the 2026 expanded agreement; NVIDIA also made an equity investment (November 2024).
  3. Milestone Payments: Preclinical, clinical development, regulatory, and sales milestones up to $232M per program. Incyte deal could pay over $1B in milestones across the five initial targets, with several billion more possible with additional targets.
  4. Royalties on Approved Products: Tiered royalties on sales of any approved collaboration products commercialized by partners.
  5. Recurring Research Funding: Recurring research funding from Incyte to support AI model training and inference compute workloads as part of the expanded 2026 agreement.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractBespoke multi-target partnership pricing negotiated per pharma collaboration

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Genesis Molecular AI product offering

Product offering

Core offering

Genesis Molecular AI builds GEMS (Genesis Exploration of Molecular Space), an AI operating system for drug discovery that integrates proprietary foundation models, autonomous agents, and exploratory tooling used by chemists across the design-make-test cycle. The platform is powered by Pearl, a generative 3D foundation model for protein-ligand cofolding, and is deployed both into partners' R&D workflows via multi-target collaborations and into Genesis's own internal small molecule pipeline.

Product overview

Genesis Molecular AI offers a unified platform-plus-foundation-model product architecture. The flagship offering is GEMS (Genesis Exploration of Molecular Space), the AI operating system for drug discovery, which integrates foundation models, agents, and exploratory tooling for chemists. GEMS is powered by Pearl, Genesis' industry-leading foundation model for 3D biomolecular structure prediction that was the first model to clearly surpass AlphaFold 3 on protein-ligand cofolding. The architecture also includes DeCAF-Pearl (a distilled flow map variant achieving ~5x inference speedup) and the production Pearl System (which adds inference-time scaling and physics+AI-based pose ranking). GEMS powers both Genesis' internal wholly-owned pipeline (oncology programs including PIK3CA and programmed cell death, plus immunology programs) and major pharma partners' pipelines (Incyte multi-target collaboration in oncology, hematology, and inflammation; Gilead multi-target collaboration against hard-to-drug targets).

Differentiator

Problem solved

Functional benefit

Brands

  • GEMS: Genesis Exploration of Molecular Space — the AI operating system/platform for drug discovery integrating foundation models, agents, and exploratory tooling for chemists.
  • Pearl

Products and services

  • GEMS (Genesis Exploration of Molecular Space) End-to-end agentic AI platform for small molecule drug discovery that integrates foundation models, autonomous agents, and exploratory chemistry tooling; used by pharma partners (Incyte, Gilead) and Genesis's internal discovery teams to generate, predict, and triage drug candidates.
  • Pearl Foundation Model Generative 3D foundation model for protein-ligand cofolding and structure prediction built on a SO(3)-equivariant diffusion architecture trained on physics-based proprietary synthetic data; achieves sub-angstrom accuracy and powers GEMS for both internal pipeline and partner programs.
  • DeCAF-Pearl (Denoiser Cofolding All-atom Flowmap model) First flow map model for all-atom cofolding, distilled from Pearl, providing ~5x faster inference at near-teacher accuracy to support high-throughput virtual screening and large-scale synthetic data generation for GEMS.
  • Pearl System (Production Cofolding System) Production cofolding system combining the Pearl foundation model with inference-time scaling techniques and physics+AI-based pose ranking, deployed inside GEMS to support active drug discovery programs against hard-to-drug targets.
  • Multi-Target Pharma Collaboration (Incyte) Bespoke multi-year, multi-target collaboration service where Genesis deploys the GEMS platform and forward-deployed drug hunters and engineers alongside partner R&D teams to co-develop differentiated small molecule drug candidates against partner-selected targets; includes exclusive development/commercialization rights, milestone payments, and royalties for the partner.
  • Multi-Target Pharma Collaboration (Gilead) Bespoke multi-year, multi-target collaboration service where Genesis deploys the GEMS platform against hard-to-drug targets selected by Gilead; deal economics include upfront cash, milestone payments, and royalties on approved products.

Quantifiable outcome

  • 15% relative improvement over AlphaFold 3 on Runs N' Poses protein-ligand cofolding benchmark
  • +5 more outcomes

Companies that use Genesis Molecular AI

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Genesis Molecular AI technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability8 records

Feature12 records

Genesis Molecular AI partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship and minor.

  • IncyteflagshipStrategic or Co-development Partner · 20 May 2026Significant expansion of the 2025 collaboration. Genesis receives $120M upfront ($80M cash + $40M equity) plus recurring research funding and is eligible for up to $232M in milestones per program, $1B+ in total milestones across five initial targets, and royalties. Incyte will provide proprietary experimental data to train GEMS — among the first major pharma-AI collaborations to power foundation model training with a partner's proprietary data. The companies will add at least five new collaboration targets (with the option to nominate more), and Incyte will have exclusive rights to develop and commercialize any resulting products.
  • IncyteflagshipStrategic or Co-development Partner · 1 February 2025Initial 2025 strategic AI-focused research collaboration. Genesis received $30M upfront for two oncology targets using the GEMS AI platform. Genesis and Incyte are co-developing differentiated small molecule drug candidates against Incyte-selected targets, with Genesis providing AI-driven design and Incyte providing R&D and commercial capabilities.
  • NVIDIAflagshipStrategic or Co-development Partner · 13 November 2024Equity investment and collaboration to optimize key computational methods for AI-powered drug discovery. Jointly announced Pearl at GTC 2025, with co-authorship of Pearl's technical report. NVIDIA's cuEquivariance kernels provide up to 15% training speedup and up to 80% inference speedup; collaboration accelerated Pearl inference 10–80% and unlocked 2.3–2.8x end-to-end speedup on B200 vs. baseline H100. NVIDIA's Triton and cuEquivariance were instrumental in accelerating Pearl inference.
  • GileadflagshipStrategic or Co-development Partner · 10 September 2024Strategic collaboration to discover and develop novel therapies. Genesis received $35M upfront payment to collaborate on 3 initial hard-to-drug targets using the GEMS AI platform. The companies work closely together on discovery and development.
  • OpenBind ConsortiumminorOthersOpenBind Consortium provided the first public structure-affinity benchmark for structure-based molecular AI; Genesis evaluated Pearl on OpenBind's EV-A71 2A 802-compound benchmark, achieving state-of-the-art zero-shot performance.
  • Massachusetts Institute of Technology (MIT)minorStrategic or Co-development PartnerResearch collaboration with Ron Shprints, Peter Holderrieth, Juno Nam, Rafael Gómez-Bombarelli, and Tommi Jaakola on the DeCAF-Pearl work and related research.
  • Carnegie Mellon UniversityminorStrategic or Co-development PartnerResearch collaboration with Nicholas Matthew Boffi on the DeCAF-Pearl work and related research.
  • University College London / MilaminorStrategic or Co-development PartnerResearch collaboration with Joey Bose (UCL and Mila) on the DeCAF-Pearl work and related research.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Genesis Molecular AI competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput wet-lab experimentation with foundation models and partnering with major pharma (Roche/Genentech, Bayer, Sanofi). Comparable in scale, multi-target partnership model, and ambition to industrialize early-stage discovery.
  • Isomorphic Labs: Alphabet/DeepMind spinout applying AlphaFold-derived foundation models to small molecule and biologics drug discovery, with multi-target pharma partnerships (e.g., Novartis, Eli Lilly). Directly comparable AI-first discovery platform with anchor pharma deals and proprietary structure-prediction models.
  • Insitro: AI-driven drug discovery company combining ML, induced pluripotent stem cell biology, and high-throughput data generation, with multi-year partnerships with Bristol Myers Squibb, Gilead, and Eli Lilly. Closely comparable in business model, partnership economics, and biotech+ML integration thesis.
  • Xaira Therapeutics: AI drug discovery company launched in 2024 with ~$1B from Sequoia and a re-purposed Illumina R&D engine, focused on foundation models for biology and small molecules. Comparable as a well-capitalized AI drug-discovery platform pursuing both partnerships and internal programs.
  • Schrödinger, Inc. Public computational chemistry and AI drug discovery company offering physics-based simulation platforms and co-developing an internal and partnered pipeline. Comparable in combining physics-based and ML approaches and selling into pharma R&D, though more mature and platform-product-led.
  • Generate Biomedicines: Flagship Pioneering-backed AI drug discovery company developing generative foundation models (e.g., Chroma) for proteins and increasingly small molecules, with major pharma partnerships (e.g., Novartis, Amgen). Closely comparable in generative AI foundation-model thesis and enterprise partnership model.
  • Exscientia: Public AI-driven small molecule discovery company with end-to-end platform and pharma partnerships (e.g., Sanofi, Bristol Myers Squibb, Roche). Closely comparable in target class (small molecules), partnership economics, and platform-plus-internal-pipeline strategy.
  • Atomwise: AI drug discovery company using structure-based and 3D molecular models (AtomNet) to discover small molecules, with a broad portfolio of pharma partnerships. Comparable in leveraging 3D structure prediction and partnership-led GTM, though earlier-stage and narrower on foundation-model capability.
  • BenevolentAI: Public AI drug discovery company focused on target identification and small molecule design, with pharma collaborations (e.g., Merck KGaA, AstraZeneca). Comparable in AI-first small-molecule and target discovery positioning, though differentiated by an emphasis on target ID over cofolding.

Emerging players

  • Iambic (formerly Entos): AI-driven small molecule discovery company combining physics-based simulation with generative AI, with NVIDIA collaboration and a partnership with AstraZeneca/Illumina. Closely comparable in NVIDIA partnership pattern and physics+ML foundation, though smaller in scale and fewer named anchor pharma partners.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Genesis Molecular AI social profiles

Digital presence

Genesis Molecular AI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genesis Molecular AI leadership team

Management profile

Number of profiles

Profiles13 records

Genesis Molecular AI funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genesis Molecular AI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genesis Molecular AI

What does Genesis Molecular AI do?

Genesis Molecular AI builds GEMS (Genesis Exploration of Molecular Space), an AI operating system for drug discovery that integrates proprietary foundation models, autonomous agents, and exploratory tooling used by chemists across the design-make-test cycle. The platform is powered by Pearl, a generative 3D foundation model for protein-ligand cofolding, and is deployed both into partners' R&D workflows via multi-target collaborations and into Genesis's own internal small molecule pipeline.

Is Genesis Molecular AI a public or private company?

Genesis Molecular AI is a private company. It is classified as venture growth investor backed and is currently operating.

When was Genesis Molecular AI founded?

Genesis Molecular AI was founded in 2019. It employs 101 to 250 people.

Where is Genesis Molecular AI based?

Genesis Molecular AI is headquartered in Burlingame, United States, in the North America region.

How does Genesis Molecular AI make money?

Five revenue lines are on record. Partnership Upfront Cash Payments are the primary driver. The others are equity Investments from Partners, milestone Payments, royalties on Approved Products and recurring Research Funding.

Who are Genesis Molecular AI's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Isomorphic Labs, Insitro, Xaira Therapeutics, Schrödinger, Inc., Generate Biomedicines, Exscientia, Atomwise and BenevolentAI. Iambic (formerly Entos) is listed as an emerging player.

Does Genesis Molecular AI have an API?

No public API is recorded for Genesis Molecular AI.

What industry is Genesis Molecular AI in?

Genesis Molecular AI's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HDAAACAA, Foundation Model Developers (LLM/Multimodal Model Labs). Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageGenesis Molecular AI announces potency prediction breakthrough with Ruby, releases potency training datasetGenesis Molecular AI announced Ruby, a model that predicts small-molecule potency, achieving the highest average correlation on four public benchmarks and ranking compounds more accurately than other methods. The model scores compounds in 25 milliseconds and is faster than evaluated alternatives. Genesis is releasing a curated training dataset, GenesisPotency-2026, under a Creative Commons license.BioSpaceIncyte Reports Second Quarter 2026 Financial Results and Provides Business UpdatesIncyte reported Q2 2026 total revenue of $1.67 billion and total net sales of $1.49 billion, up 38% and 40% year-over-year. The company raised its full-year 2026 net sales guidance to $5.13–5.26 billion, citing the Opzelura CMS agreement and Vega acquisition.BioWorldGenesis Molecular AI discloses new PI3Kα mutant inhibitorsGenesis Molecular AI Inc. has synthesized new phosphatidylinositol 3-kinase α (PI3Kα) mutant inhibitors, potentially useful for cancer treatment. The company disclosed these inhibitors on July 16, 2026, in a BioWorld Science report.Latent🔬 The Coolest Diffusion Research Isn't in LLMs — Evan Feinberg & Sergey Edunov, Genesis Molecular AIGenesis Molecular AI's co-founder Evan Feinberg and CTO Sergey Edunov discussed their PEARL model for 3D protein-ligand structure prediction, which outperforms public benchmarks on the OpenBind evaluation by accurately modeling induced fit without requiring lengthy molecular dynamics simulations. The company has developed an internal agentic drug-discovery system that can iterate like a chemist, and their automated lab partnership with Incyte enables continuous molecule generation and testing. The hosts argue that diffusion research in 3D structure prediction has been more innovative than LLM architecture development, and suggest the academic community should reassess its 2 Angstrom RMSD benchmark threshold.The Pharma LetterIncyte and Genesis expand molecular AI collaborationIncyte and Genesis Molecular AI expanded their collaboration, using Incyte's proprietary experimental data to train Genesis' drug discovery platform. The deal includes $120 million upfront and approximately $5 billion for up to 20 potential targets. It is among the first major pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary data.Business Wire BlogIncyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug DiscoveryIncyte and Genesis Molecular AI announced a significant expansion of their strategic collaboration to use AI for accelerating drug discovery, with Genesis receiving $120 million upfront (including an $80 million cash payment and $40 million equity purchase) and potential milestone payments exceeding $1 billion across five initial collaboration targets. The expanded partnership will broaden the deployment of Genesis' AI platform GEMS across a wider variety of challenging targets in Incyte's portfolio, with Incyte gaining exclusive rights to develop and commercialize any resulting products. The collaboration reflects strong results from initial programs and marks among the first major pharma-AI partnerships to power large-scale foundation model training with a partner's proprietary experimental data.IncyteIncyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug DiscoveryIncyte and Genesis Molecular AI expanded their collaboration to train Genesis' GEMS AI platform on Incyte's proprietary data. Genesis will receive $120M upfront plus potential milestone payments up to $232M per program and royalties. Incyte will add at least five new collaboration targets.BioSpaceIncyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug DiscoveryIncyte and Genesis expanded their molecular AI collaboration, with Incyte sharing proprietary data to train Genesis' GEMS platform. Genesis will receive $120M upfront plus potential milestones up to $232M per program and over $1B if all five targets succeed. Incyte holds exclusive rights to develop and commercialize any collaboration products.FinancialContent Business PageThe Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug DiscoveryGoogle DeepMind, a subsidiary of Alphabet Inc., open-sourced AlphaFold 3 in November 2024, democratizing AI-driven drug discovery by making the model's code and weights available for non-commercial academic use—a move that followed the 2024 Nobel Prize in Chemistry awarded to DeepMind founders Demis Hassabis and John Jumper for their work on protein structure prediction. This release triggered a pharmaceutical arms race, enabling Isomorphic Labs (DeepMind's commercial spin-off) to secure multi-billion dollar deals targeting "undruggable" proteins, while AI-native biotech companies like Recursion Pharmaceuticals and NVIDIA-backed Genesis Molecular AI built specialized models on the AF3 framework. The shift has compressed the "Hit-to-Lead" drug discovery phase from two to three years down to four months and is paving the way for autonomous "Self-Driving Labs" and the first fully AI-designed drugs entering Phase III clinical trials.Business Wire BlogGenesis Molecular AI Appoints Sergey Edunov as Senior Vice President of Foundation Models, Further Strengthening Leadership in Machine LearningGenesis Molecular AI announced the appointment of Sergey Edunov as Senior Vice President of Foundation Models. Edunov, with experience from Meta's AI research, specializes in large-scale generative AI models and will help scale Genesis's GEMS platform for drug discovery. The company aims to accelerate the development of treatments for complex diseases.